Introduction
============

Despite advances in the development of novel treatment methods, epithelial ovarian cancer (EOC) is still the leading cause of death from gynecologic cancer[@B1], [@B2]. Overall, 85% of ovarian cancer patients will have recurrent disease[@B3]. Secondary cytoreductive surgery (SCS) is a recommended optional treatment for recurrent ovarian cancer (ROC)[@B1]. However, only a small proportion of patients actually undergo SCS. Little is known about the expression and clinical significance of biomarkers in tumor specimens taken from ROC during SCS.

Among the biomarkers for EOC, human epididymis protein 4 (HE4) is regarded as one of the most promising serum biomarkers[@B4], because numerous studies have investigated its role in the diagnosis, prognosis, and follow-up of EOC and found that HE4 is a more valuable serum biomarker than CA125, currently a routine biomarker in the diagnosis of EOC and its recurrence[@B5]-[@B7]. Previous studies have also reported that high serum levels of HE4 correlate with both chemoresistance and a decrease in survival of women with EOC[@B8], [@B9]. However, to our knowledge, no reports have examined the expression of HE4 in ROC specimens taken from SCS. So we selected HE4 as a target biomarker in the present study.

Eukaryotic translation initiation factor 3a (eIF3a) is the core subunit of the eIF3 complex, which is crucial for the initiation of mRNA translation, and links translation initiation to transcription[@B10], [@B11], to mRNA export[@B12], and to the nonsense-mediated decay pathway[@B13]. eIF3a is under extensive investigation as a potential prognostic biomarker for different malignancies[@B14]-[@B18]. We previously presented a pilot study on the increased expression of eIF3a in primary EOC tumors, and a positive correlation between eIF3a and HE4[@B17], [@B19]. Consequently, the expression of eIF3a in tumor specimens from SCS has aroused our interest.

In the present study we used immunohistochemistry (IHC) to investigate the expressions of HE4 and eIF3a in women with ROC who underwent SCS. Furthermore, we evaluated the relationships between these biomarkers and clinicopathological parameters and survival of women with ROC.

Materials and Methods
=====================

Patients and specimens
----------------------

To obtain tumor specimens, we screened all ovarian cancer patients at the Hunan Cancer Hospital (Changsha, China) from January 2004 to December 2014. After applying our inclusion and exclusion criteria we were left with 35 patients. Our inclusion criteria were: (a) all patients had undergone both initial cytoreductive surgery (ICS) and SCS at the same hospital; (b) all specimens were confirmed histologically as epithelial ovarian carcinoma by a pathologist with expertise in gynecologic cancer. Our exclusion criteria included metastatic or non-epithelial ovarian tumors. All patients were staged according to the International Federation of Gynecology and Obstetrics (FIGO) surgical staging system. Tumor specimens and clinical data were collected from the Department of Pathology, Hunan Cancer Hospital, as approved by the Ethics Committee of Hunan Cancer Hospital (Changsha, China).

IHC detection
-------------

The procedure used in this study was described previously[@B17], [@B19]. Tumor sections (4 μm thick) were prepared from paraffin samples. After deparaffinization and rehydration, IHC was performed using an UltraSensitiveTM SP IHC Kit (Fuzhou Maixin) and a DAB Detection Kit (Streptavidin-Biotin, Fuzhou Maixin), following the protocol recommended by the manufacturer. The primary antibodies were anti-HE4 recombinant rabbit monoclonal antibody (1:1000, Abcam, ab109298) and anti-eIF3a recombinant rabbit monoclonal antibody (1:1000, Abcam, ab128996). Slides were assessed by two independent experienced pathologists blinded to the patient\'s status. In the case of an inconsistent score between them, a third pathologist was consulted for the final evaluation. Staining intensity was scored from 0 to 3 (0, negative; 1, weak; 2, moderate; 3, strong). The heterogeneity of staining was scored from 0 to 3, depending on the percentage of positively stained tumor cells (**0**, 0-25%; **1**, 25-50%; **2**, 50-75%; **3**, 75-100%). The intensity and heterogeneity scores were multiplied to generate the total score (TS). TS \>= 5 was considered as a high expression of HE4, while TS \< 5 was a low expression of HE4. In the case of eIF3a, TS \>= 4 was considered as high expression, while TS \< 4 was low expression.

Statistical analysis
--------------------

The data are presented as mean ± standard deviation. The paired t-test, McNemar\'s test, ANOVA test, Student\'s t-test, chi-square test, and multivariate Cox proportional hazard regression were performed as appropriate using SPSS 22.0 software. Overall survival (OS) was defined as the interval in months between the initial EOC resection and either death or the last observation. Progression free survival (PFS) was defined as the number of months from the ICS to the diagnosis of relapse. Patients that were alive at the end of follow-up were censored. OS and PFS were evaluated using the Kaplan-Meier method and log-rank test. Figures were made with Graph-Pad Prism 6.0. All p-values were two-tailed. P \< 0.05 was considered to be significant.

Results
=======

Clinicopathologic variables of patients
---------------------------------------

The cohort included 35 women with ROC, but the clinical data of two patients were missing. The median age of patients at the time of diagnosis was 49 years old and ranged from 29 to 70 years old. All patients did not receive radiotherapy or biological therapy, neither before nor after ICS, but some of them received platinum/taxane-based neoadjuvant chemotherapy (NACT). The postoperative chemotherapy they received was also a platinum/taxane-based chemotherapy. There were also two patients lacking the information on recurrence date. Therefore, Out of the 31 patients, 26 were platinum sensitive (26/31, 83.9%). The clinical and pathological information of each patient is shown in **Table [1](#T1){ref-type="table"}**.

Expressions of HE4 and eIF3a at initial and secondary cytoreductive surgery
---------------------------------------------------------------------------

The expressions of HE4 and eIF3a for each patient are listed in **Table [1](#T1){ref-type="table"}**. **Figure [1](#F1){ref-type="fig"}A** shows representative HE4 and eIF3a staining. The results of the paired t-test and McNemar\'s test both indicate that HE4 levels were similar between ICS and SCS while eIF3a levels were significantly increased at time of SCS (**Figure [1](#F1){ref-type="fig"}B**).

For ovarian cancer, residual tumor \<1 cm defines an optimal cytoreduction and fine surgical outcome (**Table [2](#T2){ref-type="table"}**, group 0cm plus group \<1cm)[@B1]. Conversely, residual tumor \>1 cm means a suboptimal cytoreduction and poor surgical outcome. In the present study, residual tumor was associated with the expressions of both HE4 and eIF3a in specimens from ICS and SCS.

For the initial surgery, patients with high HE4 expression achieved a higher incidence of optimal cytoreduction than those with low HE4 expression (**Table [2](#T2){ref-type="table"}**, P = 0.015). A similar result happened in SCS, as indicated by the higher incidence of no residual tumor in patients with high HE4 expression (**Table [2](#T2){ref-type="table"}**, P = 0.046). HE4 expression at initial surgery was not associated with residual tumor after SCS (**Table [2](#T2){ref-type="table"}**, P = 0.270), which means that HE4 expression at the time of the initial surgery cannot be used to predict the surgical outcome of SCS. However, HE4 expression at SCS was associated with the variation in residual tumor between the two surgeries. Patients with high HE4 expression at SCS were more likely to enhance their surgical outcome of SCS (**Table [3](#T3){ref-type="table"}**, 77.8% *v*s. 29.4%, P = 0.038).

For eIF3a, initial eIF3a expression was not associated with initial residual tumor (**Table [2](#T2){ref-type="table"}**, P = 0.760) but was associated with secondary residual tumor (**Table [2](#T2){ref-type="table"}**, P = 0.035). This was caused by all nine patients with low eIF3a expression at initial surgery increasing their surgical outcome from suboptimal (\>1 cm) to optimal after SCS. Secondary eIF3a expression was not associated with residual tumor either (**Table [2](#T2){ref-type="table"}**, P = 0.660). However, the difference in eIF3a expression between the two surgeries was associated with the surgical outcome of SCS. As shown in **Table [3](#T3){ref-type="table"}**, more patients in non-decreased group of eIF3a enhanced their surgical outcome of secondary surgery, compared to those in decreased group of eIF3a (60.9% *vs*. 0.0%, P = 0.041).

Expressions of HE4 and eIF3a at initial surgery did not show any difference among other clinicopathologic parameters including: FIGO stage, tumor grade, histological subtype, ascites, NACT, lymph node metastasis, menopause, and the cycles of two postoperative chemotherapies (data not shown, all P \> 0.05). For their expressions at secondary surgery, only HE4 expression was associated with tumor grade. The ratio of high HE4 expression decreased significantly in the sequence of borderline, G2, and G3 ovarian cancers: 6 (100%) *vs*. 9 (75%) *vs*. 2 (33%), P = 0.036.

Correlations of HE4 and eIF3a with survival of women with ROC
-------------------------------------------------------------

HE4 expression at the time of both initial and secondary surgeries correlated with the overall survival of women with ROC. As shown in **Figure [2](#F2){ref-type="fig"}A,B**, patients with high HE4 expression at either surgery had better survival, compared to those with low HE4 expression \[the median OS (95% CI) for high *vs.* low expression at ICS, 127.8 ± 28.3 (72.4-183.2) *vs.* 36.0 ± 5.2 (25.8-46.2) months, P = 0.011; the median OS (95% CI) for high *vs.* low expression at SCS, 127.8 ± 25.8 (77.3-178.3) *vs.* 49.3 ± 19.8 (10.5-88.0) months, P = 0.002\]. Furthermore, patients with an elevated total score (TS) of HE4 between the two surgeries showed a trend towards a longer OS, compared to those with a non-elevated TS of HE4 \[**Figure [2](#F2){ref-type="fig"}C**, the median OS (95% CI), 141.7 ± 17.6 (107.3-176.2) *vs.* 84.8 ± 5.1 (74.7-94.9) months, P = 0.076\]. This result indicates that an elevated TS of HE4 could predict better survival in women with ROC, although the difference was not significant. HE4 expression at the time of both surgeries did not correlate with PFS.

eIF3a expression at the time of both surgeries did not correlate with PFS and OS either (data not shown, all P \> 0.05). However, the difference in eIF3a expression between the two surgeries correlated with OS. Patients who decreased the TS of eIF3a at SCS would prolong their OS, compared to those with a non-decreased TS of eIF3a \[**Figure [2](#F2){ref-type="fig"}D**, the mean OS (95% CI), 133.4 ± 22.0 (90.2-176.6) *vs.* 87.3 ± 9.6 (68.4-106.2) months, P = 0.052\]. Among our patients, there was only one woman who had the combination of an elevated TS of HE4 and a decreased TS of eIF3a, so we were not able to statistically analyze the combined effect of HE4 and eIF3a on survival. However, that woman has the longest OS in our study (**Table [1](#T1){ref-type="table"}**, 150.5 months).

Next, we created a multivariable model that included following variables: initial and secondary HE4 expression (high *vs.* low), initial and secondary eIF3a expression (high *vs.* low), initial and secondary residual tumor (0 cm *vs.* \<1 cm *vs.* \>1 cm), histological subtype (serous *vs.* mucinous *vs.* others), tumor grade (borderline *vs.* G2 *vs.* G3), FIGO stage (I+II *vs.* III+IV), PFS, volume of ascites, menopause, NACT, lymph node metastasis, and the cycles of two postoperative chemotherapies. Initial HE4 expression was the only independent prognostic factor for OS (HR 8.91, 95%CI 1.65-48.03, P = 0.011), as identified using the method of forward Stepwise (Likelihood Ratio).

Discussion
==========

No data were previously reported about HE4 and eIF3a expressions in women with ROC who underwent SCS. To our knowledge, the present study revealed, for the first time, that eIF3a expression increases and HE4 expression is similar at the time of SCS, compared to the levels at initial surgery. We also demonstrated that HE4 and eIF3a expressions in paraffin-fixed ROC specimens are associated with surgical outcome, in terms of residual tumor, as well as OS in women with ROC.

Braicu et al. was the first study group to report the association between plasma HE4 levels and surgical outcome in ROC patients[@B2]. Recently, by using serum HE4 levels, Angioli et al. proposed a new predictive Secondary Cytoreduction Score (SeC-S) to determine the probability of achieving optimal SCS[@B20]. However, no previous studies reported the association between surgical outcome and HE4 expression in tumor specimens of EOC. Our findings showed that high levels of HE4 in tumor specimens from ICS or SCS correlated with optimal surgical outcome.

Furthermore, our data showed that initial eIF3a expression was associated with secondary residual tumor. This means that initial eIF3a expression can predict the surgical outcome of secondary cytoreduction. Patients with low eIF3a expression at initial surgery were more likely to achieve optimal cytoreduction in SCS, compared to those with high eIF3a expression. Consequently, the elevated TS of eIF3a meant a higher probability of enhancing residual tumor after SCS. Further study is needed to validate the potential of eIF3a as a biomarker for identifying optimal candidates for SCS.

In previous studies, HE4 and eIF3a preoperative circulatory levels and their IHC staining levels in tumor specimens from ICS were always utilized to predict the prognosis of women with EOC[@B2], [@B5], [@B8], [@B14], [@B15], [@B21]. In the present study, our data indicated that the elevated TS of HE4 between ICS and SCS, as well as high HE4 expression at either surgery, also predicted a better overall survival in women with ROC. However, this prediction is not consistent with previous reports, in which high serum levels or high IHC staining levels of HE4 meant a worse survival in women with primary EOC[@B2], [@B8], [@B9]. Similarly, our results on the survival prediction of eIF3a expression differed from those of previous studies. Our results showed that decreasing the TS of eIF3a between the two surgeries indicated better survival in ROC, while previous studies reported that high eIF3a expression correlated with better survival in primary EOC[@B14]. Our own study on eIF3a expression in primary EOC also demonstrated that high eIF3a expression in tumor specimens correlated with better OS (unpublished data).

We assume that SCS is one possible reason for the above inconsistent results. Because the biggest difference between the previous studies and the present study is SCS: that is, ROC patients in the present study all underwent SCS but none of them did in previous studies. Numerous retrospective studies have validated that SCS significantly increases OS in both platinum-sensitive and platinum-resistant ROC[@B22]-[@B25]. For women with ROC, the strongest predictor of OS is having maximal cytoreduction with minimal residual tumor, at best, no residual tumor after SCS[@B24]. Therefore, SCS is recommended by the NCCN guidelines[@B1]. In the present study, high HE4 expression correlated with optimal cytoreduction. Also, patients with high HE4 expression at SCS were more likely to enhance their surgical outcome of secondary surgery. Even though the residual tumor itself was not associated with survival in the present study (data not shown), we still speculated that SCS had a superior power than HE4 on the survival of ROC patients and even reversed the impact of HE4 on survival. As a result, ROC patients with high HE4 expression presented prolonged OS in our study, which was inconsistent with previous studies in primary EOC patients.

Like HE4, similar effect of SCS on eIF3a was found in this study. Initial and secondary eIF3a expression was not associated with the corresponding residual tumor, thus eIF3a expression at the time of both surgeries did not correlate with PFS and OS. Additionally, due to SCS, the reduction in TS of eIF3a between the two surgeries indicated a better survival in ROC, which was also inconsistent with previous studies in primary EOC patients.

Certainly, other possible biological or pathophysiological mechanism for these inconsistent results might exist, which calls for further investigation. The evident limitations of our study are its retrospective character, the small sample size, and the lack of external validation. Therefore, larger studies should be performed. CA125 was reported as a predictor of surgical outcome and prognosis in women with EOC by previous studies[@B2], [@B26], but our data on CA125 was not comparable due to differences in methods for detecting CA125 among the patients. So CA125 was excluded in this study.

In conclusion, this study is a single-center study to retrospectively investigate the role of HE4 and eIF3a in predicting surgical outcome and overall survival in ROC patients with SCS. HE4 and eIF3a expressions in tumor specimens from ICS and SCS indicate a unique impact on surgical outcome and overall survival, respectively, and this impact differed from the effect of both serum and tissue levels of HE4 and eIF3a at the time of ICS. Further, larger studies are required to determine whether these impacts are independent or related to SCS.
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![HE4 and eIF3a expressions in women with ROC. (**A**) The representative results of HE4 and eIF3a staining in IHC at 100× magnification. (a) and (c) High expression, (b) and (d) Low expression. (**B**) Comparisons of HE4 and eIF3a levels between initial and secondary surgery by paired t-test, respectively. Dashed lines indicate the mean TS of each group. Initial surgery *vs.* secondary surgery: 6.17 *vs.* 6.21 for HE4, 1.57 *vs.* 2.6 for eIF3a.](jcav09p2472g001){#F1}

![Correlation of HE4 and eIF3a expressions with OS by using the Kaplan-Meier method and log-rank test. (**A**) HE4 expression at initial surgery correlated with OS. (**B**) HE4 expression at secondary surgery correlated with OS. (**C**) Patients with an elevated TS of HE4 between the two surgeries had prolonged OS. (**D**) Patients with a decreased TS of eIF3a between the two surgeries had prolonged OS.](jcav09p2472g002){#F2}

###### 

Details of each patient.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.   TS of HE4 (I)^a^   TS of HE4 (II)^a^   TS of eIF3a (I)^a^   TS of eIF3a (II)^a^   RT\       RT\        Menopause   Ascites\   NACT   Grade   Subtype^b^   Stage   LN-M   Cycles (I)^a^   Cycles (II)^a^   PFS (months)   OS (months)   OS status^c^
                                                                                          (I)^a^\   (II)^a^\               (ml)                                                                                                                
                                                                                          (cm)      (cm)                                                                                                                                       
  ----- ------------------ ------------------- -------------------- --------------------- --------- ---------- ----------- ---------- ------ ------- ------------ ------- ------ --------------- ---------------- -------------- ------------- --------------
  1     6                  4.5                 2                    6                     \>1       0          NO          1000       NO     UNK     S            III     Neg    8               4                14.8           62.8          1

  2     6                  6                   2                    6                     NA        NA         NA          NA         NA     NA      NA           NA      NA     NA              NA               NA             NA            NA

  3     6                  6                   4                    2                     \>1       \>1        YES         2500       NO     G2      S            III     Pos    3               32               42.8           111.8         0

  4     4.5                NA                  0                    2                     \>1       0          NO          0          NO     BOL     M            III     Neg    2               5                5.8            29.1          1

  5     6                  7.5                 1                    6                     UNK       0          YES         0          NO     BOL     M            UNK     Neg    3               4                66.3           104.9         1

  6     6                  NA                  2                    4                     0         \<1        NO          0          YES    G3      O            III     Neg    9               UNK              14.9           54.2          1

  7     3                  4.5                 1                    2                     \>1       \<1        NO          0          NO     G3      O            III     UNK    16              2                13.5           28.3          1

  8     6                  9                   2                    6                     \<1       0          NO          5000       NO     BOL     M            III     Neg    6               6                6.1            123           0

  9     6                  6                   2                    4                     0         0          YES         1000       NO     G3      O            IV      Neg    6               7                55.7           89.7          1

  10    4.5                6                   4                    4                     \<1       0          NO          5000       NO     G2      S            III     Neg    14              3                25.5           32.5          1

  11    4.5                4.5                 0                    1                     \>1       \<1        YES         4800       NO     G3      S            III     UNK    2               UNK              UNK            92.6          0

  12    4.5                NA                  0                    6                     \>1       \<1        NO          3000       NO     G2      O            III     UNK    5               3                UNK            47.9          0

  13    3                  3                   1                    2                     0         0          NO          0          NO     G3      O            III     Pos    11              4                14.9           36            1

  14    3                  3                   2                    3                     \<1       0          YES         3800       NO     G2      S            IV      UNK    7               4                17.8           31.4          1

  15    2                  1.5                 1                    3                     \>1       0          YES         3000       NO     G2      S            III     Pos    8               8                39.1           87            0

  16    4.5                4.5                 3                    4                     \>1       \<1        YES         2500       NO     G2      O            IV      UNK    3               14               45.5           63            1

  17    NA                 NA                  0                    0                     \>1       0          YES         7000       NO     BOL     M            UNK     UNK    0               UNK              8.9            46\.          1

  18    5                  NA                  0                    0                     0         0          NO          0          YES    G2      O            IV      Neg    5               6                17.9           137.5         1

  19    NA                 4.5                 0                    0                     \<1       \<1        YES         0          YES    UNK     O            IV      Neg    4               5                30.3           49.3          1

  20    9                  9                   4                    0                     0         0          NO          100        NO     UNK     O            I       Neg    2               4                33.5           85.9          0

  21    9                  9                   2                    0                     0         0          NO          0          YES    BOL     S            III     Neg    2               UNK              35             77.2          0

  22    9                  6                   0                    6                     0         0          NO          3000       NO     BOL     S            III     Neg    6               7                43.3           82.7          0

  23    7.5                4.5                 NA                   NA                    \>1       \<1        NO          0          NO     G3      O            III     UNK    16              2                13.5           28.3          1

  24    6                  7.5                 2                    4                     0         0          NO          100        NO     G3      O            I       Neg    8               11               26.3           85.9          0

  25    9                  7.5                 4                    0                     0         0          NO          2500       NO     G2      O            III     Pos    6               11               9.8            48.1          1

  26    7.5                7.5                 4                    NA                    0         0          YES         0          NO     G2      O            I       Neg    4               3                29.5           75            0

  27    7.5                NA                  1                    NA                    0         0          NO          400        NO     BOL     S            UNK     UNK    0               UNK              39.7           UNK           UNK

  28    7.5                6                   2                    1                     \<1       UNK        YES         3000       NO     G2      O            III     Pos    9               2                20.5           94            0

  29    7.5                6                   NA                   NA                    0         \>1        NO          4500       NO     BOL     M            UNK     UNK    2               5                70.3           81.6          1

  30    6                  7.5                 1                    2                     0         \<1        YES         2500       YES    G2      O            III     Neg    14              UNK              10.9           141.7         1

  31    6                  6                   0                    0                     0         0          YES         0          NO     G2      S            I       Neg    7               14               35.6           84.8          1

  32    6                  7.5                 1                    1                     \>1       \<1        NO          150        NO     G2      O            III     UNK    9               20               33.6           127.8         1

  33    7.5                9                   2                    1                     0         0          YES         0          NO     BOL     O            II      Neg    3               4                43.6           150.5         1

  34    7.5                9                   2                    2                     \<1       0          YES         6000       NO     G2      S            III     Neg    8               6                49.2           131.9         0

  35    7.5                6                   NA                   NA                    NA        NA         NA          NA         NA     NA      NA           NA      NA     NA              NA               NA             NA            NA
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbr.: TS: total score; RT: residual tumor; NACT: neoadjuvant chemotherapy; LN-M: lymph node metastasis; Cycles: cycles of postoperative chemotherapy; PFS: progression free survival; OS: overall survival; NA: not available; UNK: unknown; Pos: positive; Neg: Negative; BOL: Borderline.

^a^: (I) for the initial surgery; (II) for the secondary surgery;

^b^: M=Mucinous, S=Serous, O=Others;

^c^: 1=Death, 0=Alive.

###### 

Comparisons of HE4 and eIF3a expression among groups of residual tumor size post-surgery, respectively.

                      Residual tumor                                                                                                         
  ------------------- ----------------- ---------------- ------------ ------------ ----------- ------------ ------------ ----------- ------- -------
  HE4                 Initial Surgery   Low expression   1 (11.1%)    2 (22.2%)    6 (66.7%)   0.015        5 (55.6%)    4 (44.4%)   0       0.270
  High expression     14 (66.7%)        3 (14.3%)        4 (19.0%)    15 (71.5%)   4 (19.0%)   2 (9.5%)                                      
  Secondary Surgery   Low expression    ------           ------       ------       no use      4 (44.4%)    5 (55.6%)    0           0.046   
  High expression     ------            ------           ------       13 (76.4%)   2 (11.8%)   2 (11.8%)                                     
  eIF3a               Initial Surgery   Low expression   11 (44.0%)   5 (20.0%)    9 (36.0%)   0.760        17 (68.0%)   8 (32.0%)   0       0.035
  High expression     3 (60.0%)         1 (20.0%)        1 (20.0%)    4 (80.0%)    0           1 (20.0%)                                     
  Secondary Surgery   Low expression    ------           ------       ------       no use      11 (61.1%)   6 (33.3%)    1 (5.6%)    0.660   
  High expression     ------            ------           ------       8 (72.7%)    3 (27.3%)   0                                             

^a^: analysis with chi-square test.

###### 

Associations of HE4 and eIF3a expression with the surgical outcome of SCS.

                                                             Surgical outcome of SCS                            
  ---------------------------------------------------------- ------------------------- ----------- ------------ -------
  HE4 expression at secondary surgery                        Low expression            5 (29.4%)   12 (70.6%)   0.038
  High expression                                            7 (77.8%)                 2 (22.2%)                
  Difference in eIF3a expression between the two surgeries   Decreased group           0 (0.0%)    5 (100.0%)   0.041
  Non-decreased group                                        14 (60.9%)                9 (39.1%)                

^a^: analysis with chi-square test.
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